Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies.

Alemán JO, Farooki A, Girotra M.

Endocr Relat Cancer. 2014 May 8;21(3):R247-59. doi: 10.1530/ERC-12-0400. Print 2014 Jun. Review.

PMID:
24478055
3.

Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Irvine E, Williams C.

Pharmacotherapy. 2013 Aug;33(8):868-81. doi: 10.1002/phar.1266. Epub 2013 Apr 3. Review.

PMID:
23553655
4.

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

Deininger MW, Manley P.

Leuk Res. 2012 Mar;36(3):253-61. doi: 10.1016/j.leukres.2011.09.018. Epub 2011 Oct 11. Review.

PMID:
21996558
5.

Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Tolomeo M, Dieli F, Gebbia N, Simoni D.

Anticancer Agents Med Chem. 2009 Oct;9(8):853-63. Review.

PMID:
19538165
6.

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.

Breccia M, Alimena G.

Leuk Res. 2009 Jul;33(7):871-5. doi: 10.1016/j.leukres.2009.01.040. Review.

PMID:
19307018
7.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

8.

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M.

Haematologica. 2005 Apr;90(4):534-41.

9.

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.

Rohon P, Porkka K, Mustjoki S.

Eur J Haematol. 2010 Nov;85(5):387-98. doi: 10.1111/j.1600-0609.2010.01501.x.

PMID:
20662899
10.

Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.

Meggyesi N, Kozma A, Halm G, Nahajevszky S, Bátai A, Fekete S, Barta A, Ujj G, Lueff S, Sipos A, Adám E, Bors A, Reményi P, Masszi T, Tordai A, Andrikovics H.

Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14.

PMID:
22005133
11.

Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.

Jabbour E, Cortes J, Kantarjian H.

Curr Opin Oncol. 2006 Nov;18(6):578-83. Review.

PMID:
16988578
12.
13.

[Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].

Nasr R, Bazarbachi A.

Pathol Biol (Paris). 2012 Aug;60(4):239-45. doi: 10.1016/j.patbio.2012.05.010. Epub 2012 Jun 26. Review. French.

PMID:
22743097
14.

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.

Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H.

Semin Hematol. 2007 Jan;44(1 Suppl 1):S25-31. Review.

PMID:
17292738
15.

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

Giles FJ, O'Dwyer M, Swords R.

Leukemia. 2009 Oct;23(10):1698-707. doi: 10.1038/leu.2009.111. Epub 2009 May 28. Review.

PMID:
19474800
16.

New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia.

le Coutre P, Schwarz M, Kim TD.

Clin Cancer Res. 2010 Mar 15;16(6):1771-80. doi: 10.1158/1078-0432.CCR-09-2760. Epub 2010 Mar 2.

17.

Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.

Hartmann JT, Haap M, Kopp HG, Lipp HP.

Curr Drug Metab. 2009 Jun;10(5):470-81. Review.

PMID:
19689244
18.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
19.

Therapy options in imatinib failures.

Ramirez P, DiPersio JF.

Oncologist. 2008 Apr;13(4):424-34. doi: 10.1634/theoncologist.2007-0170. Review.

20.

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Piccaluga PP, Paolini S, Martinelli G.

Cancer. 2007 Sep 15;110(6):1178-86. Review.

Supplemental Content

Support Center